Financials data is unavailable for this security.
View more
Year on year Regenxbio Inc has grown net income from a loss of -263.49m to a smaller loss of -227.10m despite declining revenues.
| Gross margin | 87.18% |
|---|---|
| Net profit margin | -110.29% |
| Operating margin | -96.04% |
| Return on assets | -34.07% |
|---|---|
| Return on equity | -76.88% |
| Return on investment | -43.55% |
More ▼
Cash flow in USDView more
In 2024, Regenxbio Inc increased its cash reserves by 62.93%, or 23.00m. Cash Flow from Investing totalled 103.45m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 173.13m for operations while cash generated from financing totalled 92.68m.
| Cash flow per share | -3.16 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.19 |
|---|---|
| Tangible book value per share | 3.19 |
More ▼
Balance sheet in USDView more
| Current ratio | 2.66 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 1.19 |
|---|---|
| Total debt/total capital | 0.5427 |
More ▼
